AGI Therapeutics seeks partner for Rezular
This article was originally published in Scrip
Executive Summary
AGI Therapeutics is to seek a partner for Rezular to treat diarrhoea-predominant irritable bowel syndrome (IBS-D). The product is to enter the Ardis-1 pivotal Phase III efficacy study, involving 711 patients from the US, Europe and South America, with results expected by June.